To include your compound in the COVID-19 Resource Center, submit it here.

Akcea discloses new thrombocytopenia case for volanesorsen

Akcea Therapeutics Inc. (NASDAQ:AKCA) disclosed an additional case of grade 4 thrombocytopenia in an open-label extension of its volanesorsen (IONIS-APOCIIIRx) to treat familial chylomicronemia syndrome (FCS), a rare lipid

Read the full 290 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE